CY1109734T1 - Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης - Google Patents
Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζηςInfo
- Publication number
- CY1109734T1 CY1109734T1 CY20101100028T CY101100028T CY1109734T1 CY 1109734 T1 CY1109734 T1 CY 1109734T1 CY 20101100028 T CY20101100028 T CY 20101100028T CY 101100028 T CY101100028 T CY 101100028T CY 1109734 T1 CY1109734 T1 CY 1109734T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- halogen
- hydrogen
- independently hydrogen
- hydroxy
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 2
- -1 benzyloxy, hydroxy Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 | |
| EP05732721A EP1734959B1 (en) | 2004-04-01 | 2005-04-01 | Compounds for treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109734T1 true CY1109734T1 (el) | 2014-09-10 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100028T CY1109734T1 (el) | 2004-04-01 | 2010-01-11 | Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (https=) |
| EP (2) | EP1734959B1 (https=) |
| JP (1) | JP2007531730A (https=) |
| KR (1) | KR20070010161A (https=) |
| CN (1) | CN1946399A (https=) |
| AR (1) | AR048197A1 (https=) |
| AT (1) | ATE446754T1 (https=) |
| AU (1) | AU2005231446A1 (https=) |
| BR (1) | BRPI0509512A (https=) |
| CA (1) | CA2561162A1 (https=) |
| CL (1) | CL2009001605A1 (https=) |
| CY (1) | CY1109734T1 (https=) |
| DE (1) | DE602005017373D1 (https=) |
| DK (1) | DK1734959T3 (https=) |
| DO (1) | DOP2005000050A (https=) |
| ES (1) | ES2334241T3 (https=) |
| GT (1) | GT200500063A (https=) |
| IL (1) | IL178168A0 (https=) |
| MX (1) | MXPA06011222A (https=) |
| PA (1) | PA8628601A1 (https=) |
| PL (1) | PL1734959T3 (https=) |
| PT (1) | PT1734959E (https=) |
| SI (1) | SI1734959T1 (https=) |
| SV (1) | SV2006002069A (https=) |
| TW (1) | TW200602040A (https=) |
| WO (1) | WO2005097122A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR063280A1 (es) | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| JP2010506853A (ja) * | 2006-10-12 | 2010-03-04 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物 |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| AU2010256541B2 (en) * | 2009-06-03 | 2016-03-10 | Marquette University | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| MX2012004373A (es) | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| AU2020242978B2 (en) | 2019-03-19 | 2025-10-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| NZ312577A (en) * | 1995-07-27 | 1999-08-30 | Hoechst Marion Roussel Inc | Use of optionally substituted n-(pyrrol-1-yl)-pyridinamines as anticonvulsant agents |
| AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| PL338013A1 (en) | 1997-07-16 | 2000-09-25 | Novo Nordisk As | Derivatives of condensed 1,2,4-thiadiazine, their production and application |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en not_active Ceased
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Ceased
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es not_active Expired - Lifetime
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de not_active Expired - Lifetime
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Expired - Lifetime
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL178168A0 (en) | 2006-12-31 |
| GT200500063A (es) | 2005-10-14 |
| MXPA06011222A (es) | 2007-01-16 |
| CL2009001605A1 (es) | 2009-11-27 |
| SV2006002069A (es) | 2006-05-24 |
| JP2007531730A (ja) | 2007-11-08 |
| AR048197A1 (es) | 2006-04-05 |
| EP2138176A1 (en) | 2009-12-30 |
| DE602005017373D1 (de) | 2009-12-10 |
| DK1734959T3 (da) | 2010-03-08 |
| BRPI0509512A (pt) | 2007-09-11 |
| CN1946399A (zh) | 2007-04-11 |
| ES2334241T3 (es) | 2010-03-08 |
| EP1734959A2 (en) | 2006-12-27 |
| PA8628601A1 (es) | 2006-05-16 |
| ATE446754T1 (de) | 2009-11-15 |
| TW200602040A (en) | 2006-01-16 |
| AU2005231446A1 (en) | 2005-10-20 |
| PT1734959E (pt) | 2009-12-24 |
| DOP2005000050A (es) | 2005-11-30 |
| WO2005097122A3 (en) | 2006-02-02 |
| PL1734959T3 (pl) | 2010-03-31 |
| SI1734959T1 (sl) | 2010-02-26 |
| WO2005097122A2 (en) | 2005-10-20 |
| US20070129403A1 (en) | 2007-06-07 |
| KR20070010161A (ko) | 2007-01-22 |
| EP1734959B1 (en) | 2009-10-28 |
| CA2561162A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109734T1 (el) | Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης | |
| RU2324684C2 (ru) | Пиримидиновые производные | |
| EA200700099A1 (ru) | Производные пиридина | |
| EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| ATE517882T1 (de) | Chinolinderivate | |
| CY1108583T1 (el) | Μεθοδος για θεραπεια σοβαρης καρδιακης ανεπαρκειας και φαρμακο για αυτη | |
| EA200970913A1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| EA200801041A1 (ru) | Ингибиторы мек и способы их применения | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| NO20053748L (no) | Pyrrolopyridazinderivater. | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| DK2040703T3 (da) | Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf | |
| CY1123161T1 (el) | Παραγωγα δι(φαινυλοπροπανοειδους) γλυκερολης για τη θεραπεια του καρκινου | |
| EA201071352A1 (ru) | Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств | |
| EA200700642A1 (ru) | Способы лечения эпилептогенеза и эпилепсии |